Apex Biotechnology Corp. (TPE:1733)

Apex Biotechnology Cash Flow Statement

Financials in millions TWD. Fiscal year is January - December.

Operating Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	190.27	162.89	128	115.78	181.79	202.22
Depreciation & Amortization	57.67	59.83	63.41	74.19	92.71	94.32
Other Amortization	0.92	1.09	1.4	1.52	1.39	1.35
Asset Writedown & Restructuring Costs	-	-	-	17.78	6	-
Loss (Gain) From Sale of Investments	4.25	-14.98	-4.23	3.96	29.48	-31.7
Stock-Based Compensation	-	-	-	-	-	1.59
Provision & Write-off of Bad Debts	-3.16	14.32	0.05	1.82	-	-3.5
Other Operating Activities	-14.49	-9.32	-11.24	10.85	-45.74	33.62
Change in Accounts Receivable	34.04	-88.39	-58.6	188.87	-1.38	-160.77
Change in Inventory	-63.35	90.52	67.61	-17.96	-116.67	-136.05
Change in Accounts Payable	33.55	-4.34	67.96	-96.22	-59.51	99.31
Change in Unearned Revenue	0.64	-51.05	51.68	-22.45	-64.02	50.45
Change in Other Net Operating Assets	40.48	-0.47	22.64	-47.74	2.56	29.02
Operating Cash Flow	280.82	160.12	328.67	230.39	26.62	179.87
Operating Cash Flow Growth	4.25%	-51.28%	42.66%	765.61%	-85.20%	-35.90%

Investing Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Capital Expenditures	-20.72	-15.26	-28.24	-21.91	-36.58	-26.59
Sale (Purchase) of Intangibles	-3.89	-4	-1.39	-3.07	-4.07	-3.6
Investment in Securities	9.8	9.8	-	-	-0.7	-2
Other Investing Activities	2.31	3.92	-5.96	2.48	-0.01	-2.83
Investing Cash Flow	-12.5	-5.54	-35.6	-22.5	-41.37	-35.02

Financing Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Short-Term Debt Issued	-	18.27	29.45	281.16	964.61	1,690
Total Debt Issued	15.09	18.27	29.45	281.16	964.61	1,690
Short-Term Debt Repaid	-	-18.27	-59.45	-301.16	-1,065	-1,540
Long-Term Debt Repaid	-	-8.72	-8.7	-8.2	-7.68	-404.2
Lease Payments	-8.88	-8.72	-8.7	-8.2	-7.68	-6.49
Total Debt Repaid	-23.96	-26.98	-68.15	-309.35	-1,072	-1,944
Net Debt Issued (Repaid)	-8.88	-8.72	-38.7	-28.2	-107.68	-254.2
Issuance of Common Stock	-	-	-	-	-	12.25
Common Dividends Paid	-119.94	-119.94	-109.95	-139.93	-129.94	-109.32
Other Financing Activities	-	-	-0.03	-0.02	0.01	-0.01
Financing Cash Flow	-128.82	-128.66	-148.67	-168.14	-237.6	-351.27

Net Cash Flow

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Foreign Exchange Rate Adjustments	14.66	8.49	6.24	10.59	28.72	-25.19
Net Cash Flow	154.16	34.41	150.64	50.34	-223.63	-231.61

Free Cash Flow

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Free Cash Flow	260.1	144.86	300.43	208.48	-9.97	153.28
Free Cash Flow Growth	5.03%	-51.78%	44.10%	-	-	-34.87%
Free Cash Flow Margin	13.94%	7.45%	16.22%	12.44%	-0.44%	7.19%
Free Cash Flow Per Share	2.58	1.44	2.99	2.08	-0.10	1.45
Levered Free Cash Flow	190.42	98.15	254.23	164.39	-78.18	55.06
Unlevered Free Cash Flow	192.48	100.27	256.51	167.14	-74.81	62.89
Free Cash Flow After Leases	251.22	136.14	291.73	200.28	-17.65	146.79

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash Interest Paid	3.29	3.39	3.64	4.39	5.4	4.7
Cash Income Tax Paid	24.98	21.77	48.43	18.9	24.04	9.19
Change in Working Capital	45.37	-53.73	151.29	4.5	-239.01	-118.04

Data Source: S&P Global Market Intelligence Last updated: Aug 11, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 5, 2026

Data Sources Report a data error